Swedish Orphan Biovitrum AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 6,844 million compared to SEK 5,991 million a year ago. Net income was SEK 1,026 million compared to SEK 1,386 million a year ago. Basic earnings per share from continuing operations was SEK 3.02. Diluted earnings per share from continuing operations was SEK 2.99.
For the full year, sales was SEK 22,123 million compared to SEK 18,790 million a year ago. Net income was SEK 2,409 million compared to SEK 2,638 million a year ago. Basic earnings per share from continuing operations was SEK 7.47. Diluted earnings per share from continuing operations was SEK 7.39.